Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker has acquired exclusive rights outside ...

CENTRAL GOVERNMENT FUNDS: Social welfare would account for the largest portion of the NT$3.33 trillion budget, followed by spending on education, tech and culture ...

Port Hedland is encouraging more female pilots to join WA's multi-billion dollar iron ore industry. Australia takes on Pakistan in the third ODI in Perth, with the series all square at 1-1 ...

Saudi Arabia’s Al-Jawf region has experienced its first snowfall, turning its arid desert landscape into an unexpected winter scene. This rare event followed days of heavy rain and hailstorms, ...